Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 10/2015

01-10-2015 | Research Article

Serum calprotectin: a new potential biomarker for thyroid papillary carcinoma

Authors: S. Tabur, H. Korkmaz, M. Özkaya, U. Elboğa, M. Tarakçıoglu, N. Aksoy, E. Akarsu

Published in: Tumor Biology | Issue 10/2015

Login to get access

Abstract

The aim of this study was to evaluate serum calprotectin levels and oxidative stress status in patients with papillary thyroid carcinoma (PTC) and the changes in their levels after total thyroidectomy. The study involved 30 patients with PTC and 30 healthy controls. Blood samples were obtained from the PTC patients before and 1 month after the operation. Preoperative and postoperative serum samples from PTC patients and healthy controls were analysed for calprotectin, total antioxidant status (TAS), total oxidant status (TOS) and lipid hydroperokside (LOOH). The preoperative calprotectin, TOS, OSI and LOOH levels of the patients with PTC were significantly higher compared to those of the control group (p < 0.001, for each). The levels of calprotectin decreased significantly in patients with PTC after the operation (p < 0.001), while TAS, TOS and OSI levels remained unchanged (p = 0.313, p = 0.085 and p = 0.163, respectively). Preoperative serum calprotectin levels were positively correlated with TOS, OSI and LOOH levels and negatively correlated with TAS levels in patients with PTC. In conclusion, serum calprotectin levels is increased in patients with PTC, and calprotectin is positively correlated with TOS and LOOH. Serum calprotectin levels is significantly decreased after total thyroidectomy.
Literature
1.
Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454:436–44.CrossRefPubMed
2.
Stríz I, Trebichavský I. Calprotectin—a pleiotropic molecule in acute and chronic inflammation. Physiol Res. 2004;53:245–53.PubMed
3.
Chen KT, Kim PD, Jones KA, Devarajan K, Patel BB, Hoffman JP, et al. Potential prognostic biomarkers of pancreatic cancer. Pancreas. 2014;43:22–7.CrossRefPubMed
4.
Arai K, Teratani T, Kuruto-Niwa R, Yamada T, Nozawa R. S100A9 expression in invasive ductal carcinoma of the breast: S100A9 expression in adenocarcinoma is closely associated with poor tumour differentiation. Eur J Cancer. 2004;40:1179–87.CrossRefPubMed
5.
Grebhardt S, Müller-Decker K, Bestvater F, Hershfinkel M, Mayer D. Impact of S100A8/A9 expression on prostate cancer progression in vitro and in vivo. J Cell Physiol. 2014;229:661–71.CrossRefPubMed
6.
Arai K, Yamada T, Nozawa R. Immunohistochemical investigation of migration inhibitory factor-related protein (MRP)-14 expression in hepatocellular carcinoma. Med Oncol. 2000;17:183–8.CrossRefPubMed
7.
Lehmann FS, Trapani F, Fueglistaler I, Terracciano LM, von Flüe M, Cathomas G, et al. Clinical and histopathological correlations of fecal calprotectin release in colorectal carcinoma. World J Gastroenterol. 2014;20:4994–9.CrossRefPubMedPubMedCentral
8.
Ni Bhriain H, Trovik J, Wik E, Stefansson IM, Akslen LA, Salvesen HB, et al. Plasma calprotectin concentrations in women with endometrial carcinoma. Gynecol Oncol. 2009;114:491–5.CrossRefPubMed
9.
Ødegaard E, Davidson B, Elgaaen BV, Fagerhol MK, Engh V, Onsrud M, et al. Circulating calprotectin in ovarian carcinomas and borderline tumours of the ovary. Am J Obstet Gynecol. 2008;198:418.e1–7.CrossRef
10.
Schoppy DW, Holsinger FC. Management of the neck in thyroid cancer. Otolaryngol Clin N Am. 2014;47:545–56.CrossRef
11.
Räsänen JV, Sihvo EI, Ahotupa MO, Färkkilä MA, Salo JA. The expression of 8-hydroxydeoxyguanosine in oesophageal tissues and tumours. Eur J Surg Oncol. 2007;33:1164–8.CrossRefPubMed
12.
Cooke MS, Evans MD, Dizdaroglu M, Lunec J. Oxidative DNA damage: mechanisms, mutation, and disease. FASEB J. 2003;17:1195–214.CrossRefPubMed
13.
14.
American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167–214.CrossRef
15.
Shaha AR. TNM classification of thyroid carcinoma. World J Surg. 2007;3:879–87.CrossRef
16.
Erel O. A novel automated method to measure total antioxidant response against potent free radical reactions. Clin Biochem. 2004;37:112–9.CrossRefPubMed
17.
Erel O. A new automated colorimetric method for measuring total oxidant status. Clin Biochem. 2005;38:1103–11.CrossRefPubMed
18.
Gejyo F, Kishore BK, Arakawa M. Prolidase and prolinase activities in the erythrocytes of patients with chronic uremia. Nephron. 1983;35:58–61.CrossRefPubMed
19.
Arap K, Steghnes JP. Plasma lipid hydroperoxides measurement by an automated xylenol orange method. Anal Biochem. 2004;325:158–63.CrossRef
20.
Fujimoto H, Sangai T, Ishii G, Ikehara A, Nagashima T, Miyazaki M, et al. Stromal MCP-1 in mammary tumours induces tumour-associated macrophage infiltration and contributes to tumour progression. Int J Cancer. 2009;125:1276–84.CrossRefPubMed
21.
Foell D, Wittkowski H, Vogl T, Roth J. S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules. J Leukoc Biol. 2007;81:28–37.CrossRefPubMed
22.
Ghavami S, Kerkhoff C, Los M, Hashemi M, Sorg C, Karami-Tehrani F. Mechanism of apoptosis induced by S100A8/A9 in colon cancer cell lines: the role of ROS and the effect of metal ions. J Leukoc Biol. 2004;76:169–75.CrossRefPubMed
23.
Nagase H, Woessner Jr JF. Matrix metalloproteinases. J Biol Chem. 1992;274:21491–4.CrossRef
24.
Murao S, Collart FR, Huberman E. A protein containing the cystic fibrosis antigen is an inhibitor of protein kinases. J Biol Chem. 1989;264:8356–60.PubMed
25.
Yui S, Nakatani Y, Mikami M. Calprotectin (S100A8/S100A9), an inflammatory protein complex from neutrophils with a broad apoptosis-inducing activity. Biol Pharm Bull. 2003;26:753–60.CrossRefPubMed
26.
Ryder M, Ghossein RA, Ricarte-Filho JC, Knauf JA, Fagin JA. Increased density of tumour-associated macrophages is associated with decreased survival in advanced thyroid cancer. Endocr Relat Cancer. 2008;15:1069–74.CrossRefPubMedPubMedCentral
27.
28.
29.
Sroussi HY, Lu Y, Zhang QL, Villines D, Marucha PT. S100A8 and S100A9 inhibit neutrophil oxidative metabolism in-vitro: involvement of adenosine metabolites. Free Radic Res. 2010;44:389–96.CrossRefPubMedPubMedCentral
30.
Sroussi HY, Lu Y, Villines D, Sun Y. The down regulation of neutrophil oxidative metabolism by S100A8 and S100A9: implication of the protease-activated receptor-2. Mol Immunol. 2012;50:42–8.CrossRefPubMed
31.
Tidehag V, Hammarsten P, Egevad L, Granfors T, Stattin P, Leanderson T, et al. High density of S100A9 positive inflammatory cells in prostate cancer stroma is associated with poor outcome. Eur J Cancer. 2014;50:1829–35.CrossRefPubMed
Metadata
Title
Serum calprotectin: a new potential biomarker for thyroid papillary carcinoma
Authors
S. Tabur
H. Korkmaz
M. Özkaya
U. Elboğa
M. Tarakçıoglu
N. Aksoy
E. Akarsu
Publication date
01-10-2015
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 10/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3468-1

Other articles of this Issue 10/2015

Tumor Biology 10/2015 Go to the issue

Research Article

Preoperative serum markers for individual patient prognosis in stage I–III colon cancer

Research Article

Zinc transporter genes and urological cancers: integrated analysis suggests a role for ZIP11 in bladder cancer

Research Article

Sex-determining region Y-related high mobility group box (SOX)-2 is overexpressed in cervical squamous cell carcinoma and contributes cervical cancer cell migration and invasion in vitro

Research Article

Genetic and molecular analyses reveal G6PC as a key element connecting glucose metabolism and cell cycle control in ovarian cancer

Research Article

Association between donor and recipient smoothened gene polymorphisms and the risk of hepatocellular carcinoma recurrence following orthotopic liver transplantation in a Han Chinese population

Research Article

Long noncoding RNA CCHE1 promotes cervical cancer cell proliferation via upregulating PCNA
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits